Local drug delivery of an anti-proliferative drug from balloon catheter systems to the site of arterial injury has been attempted repeatedly over the years with limited success in drug uptake and retention. Accessibility of the drug at the site is critical to combat the body's response to the procedural trauma of angioplasty. Recently, formulations have been designed which achieve delivery of therapeutic doses of the anti-proliferative drug paclitaxel to arteries with higher efficiency and longer tissue retention. These formulations succeed through formation of a drug reservoir in the artery wall enabling release after the initial angioplasty procedure. These formulations have become the cornerstone of several drug coated balloon (DCB) technologies which have found an initial, broad therapeutic application in the treatment of stenosis of the superficial femoral artery (SFA). DCBs achieve drug delivery while leaving no implant behind and represent a new class of combination products developed at the interface of engineering, chemistry and medical science. This review article summarizes the development of the LUTONIX® drug coated balloon catheter. The introduction of DCB technology has provided clinicians and patients with new SFA treatment options while ongoing clinical evidence in additional vascular beds is generated.
Introduction
It is well documented that cardiovascular disease remains the leading cause of death in industrialized nations globally [1] . After coronary artery disease (CAD) and stroke, lower extremity peripheral arterial disease (PAD) is the third leading cause of atherosclerotic vascular morbidity, with the femoropopliteal artery being the most commonly diseased vessel in the peripheral circulation [2, 3] . In these patients, restricted blood flow causes symptoms including intermittent claudication, rest pain, and ischemic ulcers that may progress to gangrene and limb loss [4] . The primary mode of treatment for PAD is endovascular balloon angioplasty of the obstruction, the goal of which is to restore luminal diameter and blood flow. However, subsequent restenosis after percutaneous transluminal angioplasty (PTA) remains too common [5] [6] [7] .
Local drug delivery by way of drug eluting stents (DES) to reduce the rate of restenosis after percutaneous intervention has shown to be a successful approach for CAD, effectively changing the standard of care for these patients [8] [9] [10] . Drug eluting stents have been introduced to improve long-term patency in PAD patients as well [11] , although adoption has not been as comprehensive as in CAD patients. The femoropopliteal artery is subject to multidirectional mechanical forces [12] . Therefore, it is well known that stenting may not be ideal due to the potential risk of fracture and deformation [13] [14] [15] . Drug coated balloon catheters (DCB) have been developed to achieve long-term patency without leaving an implant behind in an effort to increase durable treatment options available to clinicians.
The use of balloon catheters for drug delivery for the treatment of arterial disease has been explored for over 20 years. Devices included drug delivery sleeves that fit over angioplasty catheters, porous balloons that would allow the drug to weep into the vessel wall after inflation, and double balloon systems which after inflation would block the blood vessel at the proximal and distal end allowing the occluded area to be filled with a drug formulation. Various pharmaceutical agents, such as vasodilators, antioxidants, heparin, antiproliferative agents, and gene therapy systems were delivered in preclinical studies, generating poor results [16, 17] . Interestingly, Baumbach et al. [18] delivered paclitaxel in porcine hearts with an infusion sleeve system (InfusaSleeve™), and found drug retention of about 2% in the vessel wall post-delivery. The poor efficiency of drug delivery in combination with the cumbersome nature of the devices led to poor adoption.
Early literature indicated that coating the balloon portion of a PTA catheter with the antiproliferative drug paclitaxel appeared unable to deliver a therapeutic dose [19] . However, work by Drs. Bruno Scheller and Ulrich Speck indicated that paclitaxel exposed to contrast media (Ultravist™; iopromide) increased the vascular uptake of paclitaxel [20] . This idea was adopted to create a DCB [21] , which was coated with a mixture of paclitaxel and iopromide (Paccocath™). The work of Drs. Scheller and Speck postulated that paclitaxel in combination with iopromide results in a formulation that is more effective than paclitaxel alone.
In this review, the development and biological performance of a commercially approved paclitaxel formulation, the LUTONIX® DCB coating, are discussed. This system is comprised of a semi-compliant balloon catheter and a coating of paclitaxel, sorbitol and polysorbate with a drug dose density of 2 μg/mm 2 .
Formulation development
The development of a drug coated balloon (DCB) requires exhaustive literature, bench, and preclinical evaluations. In order to efficiently navigate these challenges, the biological response to arterial injury and physiochemical properties of any proposed design must be well understood.
There is a necessary distinction of therapy modalities between drug eluting stents and DCBs. The active pharmaceutical ingredient (API) in a DES is combined with a polymer that dictates the rate of release of the drug after stent implantation. The release period of the API from the DES structure is measured in terms of weeks and there is minimal concern for loss of drug during transit to the lesion. In contrast, the API for a DCB is applied to the surface of the balloon in a formulation that should control both retention and release of the API. Furthermore, the release period for the API from a DCB is measured in tens of seconds or minutes; therefore, the efficiency of retention during tracking and subsequent release is critical to ensure therapeutic treatment. Finally, a therapeutic dose of the API delivered from a DCB should be retained by the tissue for a period of time, presenting a unique challenge to the formulation in the absence of a DES-style sustained release polymer system.
The list in Table 1 , adapted from [22] , summarizes requirements for a successful DCB. As with all combination products, the relationship between the catheter device, the drug formulation, and the manufacturing methods should be carefully evaluated.
Symptomatic cardiovascular disease is characterized by narrowing of the arteries, resulting in decreased blood flow to downstream tissues. Although necessary to achieve restoration of adequate blood flow, dilation of the stenosis via angioplasty causes substantial injury to the vessel. It has been well recognized that up to 95% of angiographically successful angioplasty procedures result in substantial injury to the treated vessel [23] . The biological response to this injury results in restenosis or renarrowing of the vessel. It has been shown that the severity of the biological response is significantly influenced by the extent of vessel injury during the initial PTA procedure [24] .
The acute effects of the angioplasty procedure include denudation of the endothelial layer, compression of plaque and cellular milieu of the lesion, and stretching of the vessel (often including dissection/ separation of the media and adventitia layers) [25] . Denudation of the endothelial layer leads to platelet and fibrin deposition on the vessel surface and the initiation of a complex biological response to the injury. The response is generally characterized by an initial phase of cytokine release, resulting in an inflammatory response including migration of leukocytes from the blood stream to the vessel. The initial inflammatory response peaks over the course of the first 1-3 days [26] . This is Table 1 Essential requirements for a successful DCB [22] .
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followed by a granulation phase, which includes migration of smooth muscle cells from the media into the neointima and hyperplastic proliferation of these cells in the neointima. The proliferative response peaks between 4 and 14 days post-injury, returning to baseline by approximately 28 days [26] . Long-term healing includes regrowth of the endothelial layer, as well as replacement of cellular tissue with extracellular matrix (ECM) proteins such as proteoglycans and collagen. A successful drug coated balloon should reduce the effects of the biochemical and cellular cascade that lead to restenosis in response to injury and healing [16] . (See Fig. 1 ) Several drugs previously used to prevent arterial restenosis by drug eluting stents were evaluated for use in the LUTONIX® DCB, including sirolimus, sirolimus derivatives, and paclitaxel.
Paclitaxel (Fig. 2 ) was identified as an ideal API to be used in a DCB due to its lipophilicity, potency in inhibiting cellular proliferation, chemical stability, and the overall body of knowledge gained through chemotherapeutic experience and DES development. It is believed that the lipophilicity plays an important role in drug uptake into the tissue.
Paclitaxel is a naturally occurring cytotoxic product originally obtained by extraction and successive purifications from select yew tree species (Taxus brevifolia, Taxus yunnanensis, etc.). The mechanism of action for paclitaxel in inhibiting cellular proliferation involves promotion of microtubule formation and inhibiting disassembly of this critical cellular structure during mitosis, arresting the cell in the G 2 /M phase [25] .
Because only a low concentration of drug remains in the artery, to achieve the desired long-term biological effect, the API should remain active at low concentrations. Paclitaxel has been extensively studied in cell cultures to determine the therapeutic range of concentrations. Literature reports of the IC 50 of the drug for inhibition of smooth muscle cell proliferation in in-vitro studies is approximately1-2 ng of drug per gram of tissue (ng/g) [27, 28] , while the IC 50 for inhibition of smooth muscle cell migration is approximately 0.4 ng/g [29] , indicating the drug is a potent cell migration and proliferation inhibitor at low concentrations.
Several suitable additives to paclitaxel were evaluated to generate the uniform coating that adheres to the balloon catheter during handling, but transfers to the vessel wall upon balloon expansion. Excipients were evaluated for their compatibility with paclitaxel, their solubility and chemical properties, as well as their biocompatibility and biodegradation characteristics. Excipients were evaluated from several different chemical classes. These included surfactants (anionic, cationic, non-ionic, and ionic), contrast agents, sugars, oils, lipids, vitamins, amino acids, peptides, proteins, fatty acids, low molecular weight oligomers, urea and mixtures thereof.
A formulation which met program goals was ultimately established. In addition to paclitaxel, the drug coating on the LUTONIX® DCB contains the excipients polysorbate, a component of FDA-approved products for IV infusion such as pediatric multivitamins, and the endogenous metabolite sorbitol. These excipients facilitate a uniform coating that adheres to the balloon catheter during handling and, during balloon inflation; these excipients facilitate API release and transfer to target artery tissue.
Coating uniformity of the chosen formulation was evaluated by two analytical techniques, Scanning Electron Microscopy (SEM) and High Performance Liquid Chromatography (HPLC), which are methods described in regulatory guidances for combination products [54] . SEM images demonstrated the coating to be uniformly distributed across the balloon surface. To verify this observation, balloons were sectioned longitudinally and circumferentially, extracted, and tested for paclitaxel content via HPLC.
The final LUTONIX® DCB coating was down selected through the use of in vitro and in vivo screening tools to identify the ideal formulation, as well as dose density, with respect to both coating robustness and tissue levels of drug uptake. Published literature has since independently confirmed that a dose of 2 μg/mm 2 of paclitaxel effectively inhibits arterial smooth muscle cell proliferation in preclinical models [30] [31] [32] [33] .
Preclinical evaluation of the LUTONIX® DCB coating
The absence of an in-vitro/in-vivo correlation model to replicate the drug delivery, biological activity, and elimination patterns seen in living tissue necessitated the use of animal testing to gain substantial understanding of the system. Preclinical assessment of the LUTONIX® DCB focused on the assessment of systemic and local tissue pharmacokinetics, as well as local and systemic pathological response to the drug dose densities. To fully characterize the effects of the drug, these studies were conducted with DCBs at the final selected dose density (2 μg/mm 2 ) as well as an exaggerated dose density to establish a safety margin.
The pharmacokinetic (PK) assessment was driven by the need to thoroughly understand the manner in which the API was transferred from the surface of the balloon to the vessel, and residence time of therapeutic drug levels in the tissue.
Comprehensive drug effect and safety assessments at both the local and systemic levels were evaluated by key histological considerations for evaluation of localized drug effect and safety which included, but not limited to, endothelial cell coverage, smooth muscle cell loss, fibrin deposition, inflammation, and proteoglycan and collagen deposition.
As the transfer of drug to the vessel wall necessitates the release of the drug coating during angioplasty, special attention must also be paid to the biological effect of the formulation in downstream tissues. Current literature suggests that for commercially available DCBs, b 20% of the drug loaded onto the catheter is transferred to the vessel wall, with the rest being shed as particulate into vessels downstream of the treatment site [34] . Considerations for preclinical evaluation of systemic and downstream effects were inclusive of, but not limited to, downstream emboli, systemic toxicity, drug-induced vascular changes to non-target tissues/organs, skeletal muscle or coronary band necrosis/ fibrosis [35, 36] .
Tissue pharmacokinetics
Pharmacokinetic studies of the LUTONIX® DCB, following GLP protocols, were conducted [33] . The study consisted of treatment with a single clinical dose (1×, 2 μg/mm 2 ) for tissue and plasma pharmacokinetic analysis through 180 days.
The tissue concentrations (Fig. 3 ) indicated a bolus delivery of drug followed by an exponential decay in tissue concentration over the course of the study. Arterial paclitaxel concentrations decreased from an initial concentration of 58,800 ng/g at 1 h to 732 ng/g at 60 days and 91 ng/g at 180 days post-DCB treatment. Paclitaxel was detected at 180 days after intervention. The drug level at 180 days could still be in the therapeutic range and provide biological effect [37] .
To understand the impact of the clinical procedure on the uptake of the drug by the treated artery, procedural variables were pre-clinically evaluated. The primary mode of action of DCBs is identical to standard PTA; mechanical dilation of the lesion to improve luminal diameter and increase blood flow. Given their similarity, the success of DCB procedures is driven by well-known procedural variables related to standard PTA (Fig. 4) . These include proper inflation time, low residual stenosis, and inflation pressure [38] . Procedural variables specific to DCB include transit time to the lesion [39] . Pre-clinical studies were conducted to evaluate the effect of these factors to drug delivery and uptake.
In the porcine SFA model, the DCB was introduced through a sheath and delivered to the artery, where the treatment was performed. The amount of time between introduction into the sheath and DCB inflation, called transit time, was varied from 30 s to 3 min. In addition, the length of time the DCB was kept inflated, called inflation time, was varied from 30 s to 3 min. These tests were conducted at 6 sites per treatment arm with an average balloon to vessel ratio (BVR) of approximately 1.3:1. All balloons were inflated to nominal pressure (6 atm). One (1) hour post-DCB delivery, arterial tissues were harvested and processed to measure the amount of drug in each artery. The arterial drug content for each test group was summarized in Fig. 5 .
Both transit time and inflation time were shown to affect the tissue drug levels post-deployment. Balloon deployment with a 30-second transit time and 3-minute inflation time showed the highest drug concentration in tissue. Conversely, balloon deployment with a 3-minute transit time and 30-second inflation showed the lowest drug concentration in tissue. Short transit times ensure minimal drug loss from the DCB to the delivery site, and prolonged balloon inflations allow for optimal transfer of the formulation to the artery wall. Measured drug concentration in tissue in the long transit, short inflation arm still resulted in therapeutic levels similar to that seen Fig. 3 , while optimal results were seen with shorter transit and longer inflation times.
In the same porcine animal model, the impact of balloon inflation pressure on drug delivery was evaluated. This study was also conducted with 6 sites per treatment arm, where the balloon inflation pressure was varied from 6 to18 atmospheres, resulting in balloon diameters up to 10% larger than the nominal diameter at the highest pressure studied. Transit time and inflation time were kept constant at 30 s and 30 s, respectively. One (1) hour post-DCB delivery, arterial tissues were harvested and processed to measure the amount of drug in each artery. The arterial drug content for each test group was summarized in Fig. 6 .
The drug concentration measured in arterial tissue increased with an increase in inflation pressure, reaching a plateau between 12 and 18 atm. Increasing inflation pressure leads to a slight increase in the diameter of the balloon, thus ensuring good contact with the vessel wall and resulting in optimal drug delivery. Measured drug concentration in tissue for the lowest inflation pressure studied still resulted in therapeutic levels similar to that seen in Fig. 3 , while optimal results were seen with higher inflation pressures.
Local and systemic safety
For the safety and safety margin studies, the femoral arteries of 45 healthy domestic swine were treated with a DCB with either a 1 × 
28-days
90-days 180-days . The treated arteries, downstream vasculature, and organs were assessed histologically at 28, 90, and 180 days post-DCB treatment [33] .
The treated arteries showed minimal endothelial loss, fibrin deposition, and inflammation with long-term dose-dependent drug effect (medial smooth muscle cell loss) peaking at 90 days for both 1 × and 4× dose (Fig. 7) . In parallel, healing of the treated arteries was evident by significantly greater medial proteoglycan and collagen deposition at 180 days. No evidence of ischemia from downstream emboli or systemic toxicity was observed even for the 4 × dosage groups. Additionally, the dose dependent response is clearly evident whereby the 4× dose density (8 μg/mm 2 ) exhibited higher levels of smooth muscle cell (SMC) loss and collagen deposition in comparison to the 1× dose density. Furthermore, there were no treatment related changes in the non-target organs/tissues (e.g., lung, liver, kidney) for the 1 × or 4 × dose at any time point.
Beyond the summary for these vascular responses, Figs. 8 and 9 illustrate the absence of any physiologically significant vascular changes for both the 1× dose density as well as the 4× at each time point of 28, 90, and 180 days.
Downstream particulate safety
The safety of the particulate shed by the LUTONIX® coating was extensively evaluated using both in-vitro and in-vivo methods in an effort to understand the volume, and biological effect of the coating that may be lost in the bloodstream during the procedure.
As described in Section 3.2, extensive histological assessment of downstream and non-target organ tissue was completed during GLP animal studies at both clinical and exaggerated doses to ensure the safety of the particulate generated by the LUTONIX® coating. In addition to the safety and safety margin studies described earlier, an additional study focused specifically on downstream and non-target organ safety was completed at an even higher dosage. Deployment of the DCB in the femoral artery would result in the particulate traveling to the capillary beds in the foot of the animal, possibly resulting in embolic events or vascular tissue reaction to the presence of paclitaxel. Histological assessment of downstream skeletal muscle and the coronary band of each animal, as well as assessment of non-target organs, was completed to evaluate the effects of downstream particulate.
Despite the excessive drug particulate exposure in this study, minimal evidence of downstream emboli or drug-induced vascular changes was found in the downstream skeletal muscle and coronary band. Noted pathologic findings included very minimal fibrinoid necrosis with loss of SMCs and inflammation, with collagen replacement of SMCs seen at the 90-day time point. There was no evidence of skeletal muscle infarction or scarring, indicating that the vascular changes observed were minor and likely to be clinically insignificant.
These findings were corroborated in a study conducted by Dr. Renu Virmani and the group at CVPath Institute [36] found of fibrinoid necrosis or embolic crystalline material in downstream tissue out to 90 days post-treatment.
Coating and durability/adhesion
A balance is required between adhesion of the coating to the balloon during handling and advancement to the lesion and release of the coating to the vessel upon deployment. Excessive adhesion to the balloon would result in ease of handling and advancement, but inadequate drug delivered to the tissue. Insufficient adhesion would result in a portion of the coating being lost during manufacturing and handling by the physician prior to use and possibly exposure of staff to paclitaxel.
The durability of multiple formulations was evaluated in a simulated clinical use study by three independent physicians. The physicians performed all device preparation per the respective device Instructions for Use (IFU) for all steps prior insertion into a patient. During this simulated use test, the amount of paclitaxel material that was lost during this handling was collected, analyzed, and compared to the recommended level of exposure of 1 ng/cm 2 [40] for surface contamination of cytotoxic drugs, see Fig. 10 . The LUTONIX® formulation consistently showed contamination levels below the recommended level for decontamination [41] . Additional functional testing to quantify drug coating adhesion was completed using samples that were again prepared per the respective IFU while incorporating a "shake" test [31] . This test consisted of measuring the amount of drug coating which fell off a balloon that was inflated and shaken in an empty vial. This representative preparation of the DCB, and subsequent adhesion evaluation, demonstrated that the LUTONIX® formulation consistently exhibited excellent coating durability (Fig. 11) [35, 42] .
Clinical experience with the LUTONIX® DCB
Clinical experience in controlled randomized studies, as well as with real world subjects, is important to evaluate the safety and effectiveness of drug coated balloons. Over 2000 patients have been treated with the LUTONIX® DCB in clinical trials, and key results are summarized in the following sections.
LEVANT 1
The first human study of LUTONIX® DCB for treatment of occlusive femoropopliteal artery disease was LEVANT 1, a prospective, multicenter, single-blind, randomized (1:1) controlled trial comparing angiographically measured Late Lumen Loss (LLL) with the LUTONIX® DCB to standard (uncoated) balloon angioplasty (PTA) [43] . Enrollment of 101 patients and 24-month follow-up have been completed.
Demographic, disease characteristics, and lesion characteristics were well matched between arms. At 6 months, LLL was 58% lower for the LUTONIX® DCB group (0.46 ± 1.13 mm) than for the control group (1.09 ± 1.07 mm; p = 0.016). Composite 24 month major adverse events were 39% for the DCB group versus 46% for PTA group. Pharmacokinetics showed a bi-phasic exponential decay with peak concentration (Cmax) of 59 ng/ml and total observed exposure (AUC all ) of 73 ng h/ml.
LEVANT 2
The LEVANT 2 study was a prospective, multi-center, single-blind, randomized, controlled trial in subjects suffering from obstructive de novo or non-stented restenotic lesions in native femoropopliteal arteries [44] . Four hundred and seventy-six (476) patients were randomized (316 DCB and 160 PTA) at 54 sites in both the United States and Europe [45] under a single protocol. After a defined pre-dilatation, the patients were randomized 2:1 to treatment with the DCB or standard PTA. Patient inclusion and exclusion criteria were similar to LEVANT 1, with a lesion length range of 4-15 cm. Patient demographics, baseline lesion characteristics, and device and procedural success were similar between arms. The study was designed to minimize bias, as patients, clinical events committee (CEC), and core laboratories were blinded to treatment group. Additionally, and unique to date only to this PAD study, a blinded physician performed follow-up clinical evaluations at 30 days, 6 months, and 12 months. Clinical visits with duplex ultrasonography to evaluate restenosis were conducted at 6, 12, and 24 months.
At 12 months, the DCB group was shown to be non-inferior to the PTA group in freedom from safety events, defined as freedom from allcause perioperative (≤30 day) death and freedom at 1 year from the following: index limb amputation (above or below the ankle), index limb re-intervention, and index limb-related death (p = 0.005). The proportion of subjects that were free from primary safety events at 12 months was 83.9% and 79.0%, for DCB and PTA, respectively. The DCB group also showed superiority over PTA in primary patency, defined as absence of target lesion restenosis and freedom from target lesion revascularization (65.2% versus 52.6%, p = 0.015). There were no unanticipated adverse device effects in the DCB arm, and overall adverse event rates were similar in the two treatment arms. Freedom from target lesion revascularization (TLR) was a secondary endpoint and was measured at 87.7% for DCB and 83.2% for PTA. The outcomes were numerically favorable for the DCB arm but were not statistically different. Following the pre-specified hierarchical method, no secondary endpoint will be discussed since the first ordered secondary endpoint (Total TLR at 12 months) failed to meet its objective. The LEVANT 2 pivotal study was not powered to statistically examine differences in results between subgroups.
To further investigate geographic differences in the LEVANT 2 study, a post-hoc sub-group analysis of German centers was conducted [46] . Among the 476 patients in LEVANT 2, 126 patients were enrolled at 8 participating German sites and were randomized 2:1 to treatment with the LUTONIX® DCB (n = 83) vs an uncoated balloon during PTA (n = 43). Demographic, clinical, and lesion characteristics were matched between LUTONIX® DCB and PTA groups, as were the final percent diameter stenosis (19%) and procedure success (91%). By Kaplan-Meier analysis, the 12-month primary patency rate was 80% vs 58% (p = 0.015) and the composite safety endpoint rate was 94% vs 72% (p = 0.001), respectively. Freedom from TLR was higher for DCBs (96%) vs PTA (82%, p = 0.012). Major adverse events were similar for both groups. Compared to the non-German LEVANT 2 cohort, there was a shorter time between insertion and inflation of treatment balloons (21.8 vs 39.5 s, p b 0.001) in the German cohort. Balloons were inflated to higher pressures (9.0 vs 7.7 atm, p b 0.001) but for a shorter period of time (130 vs 167 s, p b 0.001), and although treated lesions in the German cohort had a higher baseline stenosis, final post-procedure diameter stenosis was lower (19% vs 22%, p = 0.04) than in the non-German patients. Baseline characteristics of treated patients and lesions were generally similar for German and non-German cohorts of LEVANT 2, with a few exceptions that seem unlikely to have impacted the results. Baseline outflow and diameter stenosis were worse in German patients, but lesion length, RVD, occlusions, calcifications, Rutherford category, and ABI were all comparable. Finally, no differences in baseline variables were observed between the DCB and control groups in either the German or the global LEVANT 2 populations. Overall, this sub-group analysis concluded that geographic or regional differences in procedural variables may account for the different outcomes between the German and non-German cohorts.
Finally, to better interpret the overall results of LEVANT 2 and the observations in the German cohort, and to provide guidance to clinicians, a post-hoc correlation of 12 month outcomes from the LEVANT 2 clinical study to key procedural variables was conducted [47] .
The results suggested correlations between positive clinical outcomes and each of: final residual stenosis, balloon transit time, balloon inflation pressure, and balloon inflation time. As shown in Fig. 12 , the 12-month patency rate improved as more of the procedural best practices were applied during drug delivery. In a similar post-hoc analysis, balloon size was also suggested to be correlated with improved outcomes. Specifically, patency outcomes improved by 65.7% over standard PTA when a DCB balloon-to-artery ratio of N1.04:1 was selected.
This post-hoc analysis of LEVANT 2 data suggest that these procedural variables are critical for optimal DCB patient outcomes. Rapid transit time to the treatment site ensures minimal drug loss while the catheter is advanced to the lesion. High inflation pressure and longer inflation time ensure that the DCB fully contacts the vessel wall during drug delivery. Full vessel wall contact results in greater drug uptake and higher drug tissue content after the balloon has been withdrawn. After optimal delivery, paclitaxel dwells in tissue for prolonged time periods, and the dissolved paclitaxel from this formulation results in smooth muscle cell inhibition. Successful outcomes using balloon angioplasty require good mechanical dilatation. As the DCB also acts as a PTA catheter, low final percent diameter stenosis is a result of good mechanical dilatation with the catheter.
LUTONIX® SFA global "real world" registry
After commercial release of the LUTONIX® 035 DCB in Europe, a single arm registry study was initiated to evaluate the DCB performance in a "real world" setting. There were a total of 691 subjects enrolled in the Global SFA Registry, across 38 centers and 10 countries. All serious Fig. 12 . Primary patency rates associated with key procedural variables [47] .
adverse events (SAEs) were adjudicated by a Clinical Events Committee (CEC) and were independently monitored.
The patients enrolled in the Global SFA Registry are representative of patients with SFA disease. The patients in this study had longer lesions than what has been previously reported in LEVANT 2 with more advanced disease. The mean lesion length in the Global Registry was longer than LEVANT 2 (101.2 ± 84.2 mm vs. 62.7 ± 41.4 mm) with the maximum lesion length of 500.0 mm vs. 196.7 mm, respectively. The initial percent stenosis was higher for subjects in the Global Registry (90.0% vs. 80.5%). Chronic total occlusions (CTO) were more prevalent in the Global Registry compared to LEVANT 2 (31.2% vs. 20.6%).
The primary efficacy endpoint of freedom from TLR at 12 months was higher in the Global SFA Registry as compared to LEVANT 2 with the rate being 93.4% (605/648) vs. 87.7% (250/285). As a secondary endpoint, the 12 month patency rate of the Global SFA Registry was 83.1%. Primary patency was defined as: patency of the target lesion by investigator assessment based on presenting symptoms and clinical exam and by absence of CEC adjudicated TLR event. In the Global Registry good DCB procedures were performed with mean inflation of 108.1 ± 39.49 s, mean inflation pressure of 9.7 ± 2.21 atm, and mean residual stenosis of 14.6 ± 18.69%. Transit time was not collected in the Global Registry [48] .
The composite safety outcomes at 12 months were higher (86.8% vs. 83.9%) for the Global Registry as compared to LEVANT 2. Freedom from TLR and safety outcomes at 24 months by Kaplan Meier analysis was 90.3% and 86.7%, respectively [48] . A subgroup of Global Registry subjects with complex lesions including calcified lesions and chronic total occlusion were analyzed. Calcified lesions and chronic total occlusions (CTO) had a Freedom from TLR at 24 months of 88.3% and 89.5%, respectively [49, 50] . A long lesion subgroup, from the same study, defined as lesions ≥ 140 mm in length, was also analyzed. The mean lesion length for this subgroup was 212.3 ± 65.3 mm with a maximum lesion length of 500.0 mm. This subgroup also showed similar results at 24 months; 89.4% Freedom from TLR and 85.7% for composite safety by Kaplan Meier. The Global SFA Registry outcomes further demonstrate the durable benefits and reinforce the safety of the LUTONIX® DCB in real world patients, including those with complex lesions.
Ongoing investigational device studies
At the time of this publication, the LUTONIX® formulation is additionally being studied for safety and efficacy under IDE application in three (3) of the most difficult patient populations with PAD. First, a global randomized trial was initiated to demonstrate the superior efficacy and non-inferior safety of the LUTONIX® DCB in comparison to standard angioplasty for the treatment of stenosis or re-occlusion of below-theknee (BTK) arteries. Patients with BTK [51] disease suffer from a high failure rate with currently available treatments, which may eventually lead to amputation of the limb.
Second, a randomized trial is being conducted to demonstrate superior efficacy and non-inferior safety of the LUTONIX® DCB for treatment of in-stent restenosis (ISR) [52] lesions in the SFA in comparison to standard angioplasty. Loss of vessel patency due to the formation of neointimal hyperplasia is a well-documented limitation of stent treatment. As discussed previously, the DCB is designed to prevent smooth muscle proliferation, which is the primary cause of neointimal hyperplasia.
Finally, a randomized trial is being conducted that compares the LUTONIX® 035 DCB to the standard PTA for treatment of stenotic obstructions of arteriovenous (AV) fistula [53] . The primary underlying pathophysiologic mechanism responsible for failure of AV fistulas is obstructive lesions due to intimal hyperplasia within the access circuit.
Conclusions
The development of clinically effective drug coated balloons is attributed to formulations of paclitaxel with excipients that balance durability of the coating to the balloon during handling with release of the coating to the vessel upon deployment. The LUTONIX® drug-coated balloon formulation underwent significant development and optimization using stringent engineering, chemical, biocompatibility and pharmacology requirements. In preclinical studies, the coating balances effectiveness, i.e. drug delivery and drug retention, and safety, i.e. freedom from systemic and downstream toxicity. Extensive clinical trials demonstrated the benefit of this technology for the treatment of obstructive lesions in the SFA, while confirming minimal risks with the addition of the drug in conventional angioplasty. Additionally, through post-hoc analyses, key procedural variables that suggest good drug delivery were identified: final residual stenosis, balloon transit time, balloon inflation pressure, and balloon inflation time. The same formulation is being further studied in additional patient populations and is currently being investigated for safety and effectiveness under IDE for BTK and AV fistula indications.
